

LATEST RESEARCH PROJECT IMPROVES MANUFACTURING PROCESS FOR FLAVOCIDE™

- **Reduction in the cost of manufacturing Flavocide™ achieved**
- **New methodology delivers Flavocide with high purity and yield**
- **Facilitates transitioning process to manufacturing at pilot plant scale**

Bio-Gene Technology Limited (ASX: BGT, "Bio-Gene") is pleased to announce the completion of the latest stage of its development project with CSIRO which has improved the yield and the cost of the synthesis process for the production of flavesone, the active constituent contained within Flavocide™.

The project has successfully developed an improved process for production of flavesone in a more efficient and higher yielding manner. The new process lowers the costs of raw materials, achieves more efficient homogeneous process reactions, produces less waste material and results in finished product of high purity. Importantly it also provides significant additional intellectual property for Bio-Gene.

Richard Jagger, Bio-Gene CEO commented: "Achieving a commercially viable manufacturing process of our compound is an important milestone not only for Bio-Gene but also for prospective partners. These improvements in the manufacturing process underpin the long term supply of our product. We are now in a position to engage targeted manufacturers to undertake pilot plant production of Flavocide."

To supplement the project, Bio-Gene received a \$50,000 grant through the Australian Government's Innovations Connections program. The grant was facilitated by CSIRO's SME Connect team, who connect small and medium sized businesses with the best research expertise and capabilities to fast-track their research and development projects.

Dr Adam Meyer, Principal Research Scientist at CSIRO who led the research commented: "At CSIRO we believe in creating value for our customers and are very pleased with the results of this project. Working with Bio-Gene, CSIRO has developed a new process that not only significantly reduces cost and waste, but also improves the yield allowing for the production of flavesone at pilot plant scale."

- ENDS -

For further information, please contact:

Bio-Gene Technology Limited:

Richard Jagger
Chief Executive Officer
P: 03 9628 4178
E: bgt.info@bio-gene.com.au

Roger McPherson
CFO & Company Secretary
P: 03 9628 4178
E: bgt.info@bio-gene.com.au

Media/investor relations:

Ben Walsh or Kyahn Williamson
WE Buchan
T: 03 9866 4722
E: bio-gene@we-buchan.com

About Bio-Gene Technology Limited

Bio-Gene is an Australian agtech development company enabling the next generation of novel insecticides to address the global problems of insecticide resistance and toxicity. Its novel platform technology is based on a naturally occurring class of chemicals known as beta-triketones.

Bio-Gene Technology Limited

ABN: 32 071 735 950

Suite 1, Level 6, 50 Queen St, Melbourne, VIC 3000

Beta-triketone compounds have demonstrated insecticidal activity (e.g. kill or knock down insects) via a novel mode of action in testing performed to date. This platform may provide multiple potential new solutions for insecticide manufacturers in applications across animal health and crop protection, as well as in public health, and in consumer applications.

The Company's aim is to develop and commercialise a broad portfolio of targeted insect control and management solutions.

About CSIRO

The Commonwealth Scientific and Industrial Research Organisation (CSIRO) is Australia's national science agency and one of the largest and most diverse research agencies in the world. Its innovations contribute billions of dollars to the Australian economy every year. As the largest patent holder in the nation, CSIRO's wealth of intellectual property has led to more than 150 spin-off companies. For more information visit www.csiro.au